Psoriasis Linked to Increased Metabolic Syndrome Risk, Mediated by Disease Activity
June 16, 2025 / psoriasis risk factors / metabolic syndrome link / PASI score correlation / inflammatory skin disease / chronic disease comorbidities
Psoriasis significantly increases the risk of metabolic syndrome (MetS), with severity of disease activity correlating with higher risk. This dose-response relationship underscores the need for early detection, interdisciplinary care, and metabolic monitoring in psoriasis patients.
American Heart Association Launches Cardiovascular-Kidney-Metabolic Health Initiative
June 13, 2025 / CKM syndrome care / cardiovascular kidney metabolic / AHA health initiative / chronic disease guidelines / patient-centered certification
The American Heart Association has launched a four-year initiative to address cardiovascular-kidney-metabolic (CKM) syndrome through unified guidelines, enhanced screening, education, and clinical care across 150 U.S. sites, aiming to improve outcomes for over 265,000 patients.
How Easily You Can Access GLP-1 Meds May Depend on Your Race
June 16, 2025 / GLP-1 access disparities / obesity medication equity / racial health gaps / diabetes treatment delay / metabolic liver disease care
New research reveals that Black and Hispanic patients eligible for GLP-1 medications face delayed access compared to white patients, despite similar eligibility. These disparities persist even after adjusting for socioeconomic and health factors, highlighting systemic inequities in obesity care.
Fecal Microbiota Transplants Studied for Treating Autism and Metabolic Disorders
June 14, 2025 / Fecal microbiota transplant / FMT autism treatment / gut microbiome therapy / metabolic disorder microbiome / obesity microbiota research
Fecal microbiota transplants (FMT) show potential for treating autism, obesity, and type 2 diabetes by restoring gut microbiome balance, though long-term safety and standardized protocols remain under investigation to validate broader clinical use.
Researchers identify a protein that may help improve the treatment of obesity and cardiovascular disease
June 6, 2024 / brown adipose tissue / ACBP protein obesity / obesity cardiovascular treatment / thermogenesis fat metabolism / brown fat inactivation
Researchers have identified ACBP, a protein that suppresses brown adipose tissue activity, potentially contributing to obesity and cardiovascular disease. Targeting ACBP may offer new therapeutic strategies to enhance fat metabolism and treat cardiometabolic conditions.
A web application has been developed to improve the assessment of pediatric and adolescent cardiometabolic health.
June 16, 2025 / pediatric cardiometabolic health / childhood obesity risk / metabolic syndrome assessment / cardiometabolic app ObMetrics / adolescent health screening
Researchers developed ObMetrics, a validated web app enabling accurate, percentile-based assessment of pediatric and adolescent cardiometabolic health. It adjusts for sex, maturity, and ethnicity, improving risk interpretation across diverse populations and supporting both clinical and research use.
Diabetes drug dapagliflozin shows benefits for MASH in Phase 3 trial
June 16, 2025 / MASH treatment breakthrough / dapagliflozin liver benefits / SGLT2 inhibitors MASH / fatty liver disease therapy / metabolic liver disease drug
A Phase 3 trial shows that dapagliflozin significantly improves liver inflammation and fibrosis in patients with MASH, including those without diabetes. The SGLT-2 inhibitor reduced liver fat, body weight, and metabolic risk markers with a favorable safety profile.
D&D Pharmatech Announces Positive Phase 2 Results for DD01 in MASH with Robust Reductions in Liver Fat Accompanied by Improvements in Liver and Metabolic Health
June 16, 2025 / MASH treatment breakthrough / DD01 Phase 2 results / liver fat reduction therapy / GLP-1 glucagon agonist / nonalcoholic fatty liver disease
D&D Pharmatech’s dual GLP-1/glucagon receptor agonist, DD01, significantly reduced liver fat and improved liver stiffness, metabolic markers, and HbA1c in MASH patients after 12 weeks. The drug was well tolerated, with mostly mild gastrointestinal side effects.
Echosens and Boehringer Ingelheim Expand Long-Standing Collaboration to Accelerate Progress in MASH Diagnosis and Care
June 10, 2025 / MASH early diagnosis / non-invasive liver testing / Echosens Boehringer partnership / Survodutide clinical trials / metabolic liver disease care
Echosens and Boehringer Ingelheim are expanding their partnership to enhance early MASH diagnosis and care by promoting non-invasive testing, streamlining care pathways, and integrating diagnostics with emerging therapies like Survodutide for metabolic liver disease.
D&D Pharmatech’s DD01 Phase 2 trial success boosts stock by over 20%
June 16, 2024 / DD01 Phase 2 results / MASH liver fat reduction / D&D Pharmatech clinical trial / MASLD treatment breakthrough / FDA MASH drug development
D&D Pharmatech’s DD01 showed significant liver fat reduction in a U.S. Phase 2 MASH trial, with 75.8% of patients achieving ≥30% fat reduction, boosting investor confidence and advancing toward FDA approval benchmarks.
Daily almond snack helps people with metabolic syndrome
June 16, 2025 / almonds / metabolic syndrome / cholesterol reduction / gut health / cardiometabolic wellness
A 12-week clinical trial found that daily almond consumption improved cholesterol levels, reduced waist circumference, and enhanced gut and cardiometabolic health in adults with metabolic syndrome, highlighting almonds’ role in managing disease risk and inflammation.
Daily snack boosts the health of people at greater risk of heart disease and strokes
June 13, 2025 / almonds / metabolic syndrome / LDL cholesterol / gut inflammation / vitamin E
A 12-week study found daily almond consumption improved cardiometabolic markers in adults with metabolic syndrome, reducing LDL cholesterol, waist circumference, and gut inflammation while boosting vitamin E levels, supporting almonds as a preventive dietary intervention.
Study first to use novel glucagon isotopes to measure glucagon metabolism in Type 1 diabetes
June 12, 2025 / glucagon metabolism / Type 1 diabetes / stable isotopes / alpha cell function / dual hormone therapy
Researchers used novel stable glucagon isotopes to map glucagon metabolism in Type 1 diabetes, revealing differences in peripheral tissue extraction and offering new insights for dual hormone therapy and future diabetes drug development.
Meal and sleep timing play key roles in diabetes prevention
June 12, 2025 / meal timing / sleep quality / type 2 diabetes / circadian rhythm / metabolic health
Meal and sleep timing significantly impact glucose regulation and metabolic health in individuals at risk for type 2 diabetes, independent of calorie intake, highlighting the importance of circadian-aligned behaviors for diabetes prevention.
Uncovering the genetic link between type 2 diabetes and brain structure
June 11, 2025 / type 2 diabetes / brain structure / genetic overlap / cognitive decline / neurodegeneration
New research reveals significant genetic overlap between type 2 diabetes and subcortical brain structure abnormalities, identifying shared loci and biological pathways that may underlie cognitive decline and neurodegeneration in T2DM patients.
Long-term food pairings show strong link to cardiometabolic health
June 14, 2025 / ‘cardiometabolic health / food pairing patterns / gut microbiome / precision nutrition / metabolic disease prevention
Long-term food pairings, rather than individual food items, significantly influence cardiometabolic health by modulating gut microbiota. These synergistic or antagonistic dietary combinations offer novel insights for precision nutrition and disease prevention across diverse populations.
Deep Apple Therapeutics Announces Collaboration with Novo Nordisk to Discover and Develop Oral Therapeutics for Cardiometabolic Diseases
June 11, 2025 / cardiometabolic disease / GPCR therapeutics / obesity treatment innovation / Novo Nordisk partnership / AI drug discovery
Deep Apple Therapeutics and Novo Nordisk will co-develop first-in-class oral small molecule drugs targeting a novel non-incretin GPCR for cardiometabolic diseases, leveraging AI and cryo-EM to accelerate drug discovery and expand therapeutic options for obesity and related conditions.
Renibus Therapeutics Announces FDA Orphan Drug Designation for Veverimer for the Treatment of Anti-glomerular Basement Membrane Disease (anti-GBM)
June 10, 2025 / anti-GBM disease / veverimer FDA designation / rare kidney disease treatment / orphan drug renal therapy / Renibus Therapeutics news
The FDA has granted Orphan Drug Designation to veverimer for treating anti-glomerular basement membrane (anti-GBM) disease, a rare autoimmune kidney disorder. Veverimer targets key disease mechanisms, offering promise for this life-threatening condition with limited treatment options.
Preserving good cardiovascular health lowers the risk of mortality and MAFLD: Study
June 17, 2025 / Life’s Essential 8 / MAFLD prevention / cardiovascular health index / obesity liver disease risk / LE8 mortality reduction
High Life’s Essential 8 (LE8) scores significantly reduce cardiovascular mortality, all-cause mortality, and MAFLD risk in overweight and obese individuals, highlighting the preventive power of cardiovascular health in managing liver disease and improving survival outcomes.